| abstract |
The present invention relates to a combination therapy of an oncolytic virus, in particular an oncolytic adenovirus, and a checkpoint inhibitor for the treatment of cancer, in particular to a combination therapy comprising (a) encoding tumor necrosis factor alpha (TNFα) and/or interleukin-2 (IL-2). 2) Use of a combination as a transgenic oncolytic adenoviral vector and (b) one or more immune checkpoint inhibitors for the treatment of cancer. |